2/5
07:00 am
eypt
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
1/16
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/7
07:13 am
eypt
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 [Yahoo! Finance]
Medium
Report
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 [Yahoo! Finance]
1/7
07:00 am
eypt
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
Medium
Report
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
12/23
02:27 pm
eypt
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains [Yahoo! Finance]
Low
Report
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains [Yahoo! Finance]
12/20
07:27 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Medium
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
12/17
07:56 am
eypt
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/17
07:00 am
eypt
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/16
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Medium
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/26
06:43 am
eypt
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Low
Report
Eyepoint Pharmaceuticals (NASDAQ:EYPT) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
11/19
07:43 pm
eypt
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]
Low
Report
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review [Yahoo! Finance]
11/19
07:13 am
eypt
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration [Yahoo! Finance]
11/19
07:00 am
eypt
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
Medium
Report
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
11/17
07:00 am
eypt
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
High
Report
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)